The Ministry of Health, Labor and Welfare (MHLW) on December 18 presented a proposal to define the scope of products…
HOME > ORGANIZATION
ORGANIZATION
- Off-Year Revisions Need Careful Assessments and Discussions: Chuikyo JMA Rep
December 20, 2024
- JPMA to Continue Seeking Repeal of Off-Year Revisions: Exec
December 20, 2024
- JPA Calls for Improving Package Units as Pharmacies Suffer with Unsold Stocks of Pricey Meds
December 19, 2024
- Japan Citizens’ Group Opposes RWD-Only Drug Submissions
December 16, 2024
- EFPIA Japan Issues Joint Statement for Resolving Drug Lags/Losses
December 12, 2024
- Pharma Labor Group Petitions MHLW to Scrap Off-Year Revisions
December 3, 2024
- DPP Head, Industry Leaders United towards Stopping Off-Year Price Revisions
November 29, 2024
- PhRMA Wants No Off-Year Price Cuts, Urges Japan Not to Backslide: Chair
November 28, 2024
- JGA to Launch Study Group on Industry Revamp by End of FY2024
November 26, 2024
- Japan Pharmacy Group Demands Abolishing Off-Year Price Revisions
November 22, 2024
- Chuikyo Payer Rep Touts Necessity of FY2025 Off-Year Price Revision
November 19, 2024
- Japan, US, Europe Trade Groups Urge Ishiba Govt to Scrap Off-Year Revisions
November 18, 2024
- JPMA Appreciates Growing Calls for Abolition of Off-Year Revisions: Exec
November 15, 2024
- Osaka’s New Life Science Hub to Grow into Full Ecosystem in 5 Years: Operator
November 12, 2024
- Self-Medication and Proper Drug Pricing 2 Sides of the Same Coin: Professor
November 8, 2024
- Japan Wholesaler Group to Continue Stressing Plight of Supply Disruption
October 25, 2024
- Drug Therapy for Fetal Tachyarrhythmia Gets 1st Health Coverage in Japan
October 21, 2024
- Off-Year Price Revision Has Accomplished Mission: JPMA Exec
October 18, 2024
- JaDHA Inks MOU with DTA to Collaborate in DTx Push
October 16, 2024
- JaDHA Creates Hypothetical Case Collection to Push Two-Stage Approval of SaMD
October 11, 2024
ページ
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
Will an “off-year” drug price revision happen in April 2025 or not? Over the last week, expectations have been up…
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…